USFDA accepted the Roche’s sBLA for Tecentriq (atezolizumab) in combination with Abraxane
Posted on30 Jan 2019
Comments0
US Food and Drug Administration (FDA) has accepted the Roche’s supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane®... Read More
Case Study: US FDA priority review grants for BMS’s sBLA for Opdivo to treat patients with resected high-risk advanced melanoma
Bristol-Myers Squibb Company announced that the US Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application... Read More
What is Biologic License Application (BLA)?
Biological products are approved for marketing under the provisions of the Public Health Service (PHS) Act. The Act requires a firm who... Read More